Advertisement

Pharmaceutical Chemistry Journal

, Volume 49, Issue 12, pp 804–809 | Cite as

Synthesis, Hydrolytic Stability, and Antileukemic Activity of Azacytidine Nucleoside Analogs

  • T. S. Bozhok
  • E. N. Kalinichenko
  • B. B. Kuz’mitskii
  • M. B. Golubeva
SEARCH FOR NEW DRUGS

New azacytidine nucleoside analogs with modified carbohydrate moieties were synthesized. Screening identified a highly active 2′-fluoro-containing azacytidine analog that could potentially be of interest as an agent for treating acute myelogenous leukemia and myelodysplastic syndrome.

Keywords

myelodysplastic syndrome azacytidine glycosylation fluoro-deoxynucleosides hydrolytic stability antileukemic activity 

References

  1. 1.
    A. D. Shirin, Klin. Onkogematol., 1, No. 1, 21 – 33 (2008).Google Scholar
  2. 2.
    G. S. Mack, J. Natl. Cancer Inst., 98, No. 20, 1443 – 1444 (2006).CrossRefPubMedGoogle Scholar
  3. 3.
    J. K. Christman, Oncogene, 21(35), 5483 – 5495 (2002).CrossRefPubMedGoogle Scholar
  4. 4.
    E. A. Griffiths and S. D. Gore, Semin. Hematol., 45(1), 23 – 30 (2008).CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    J. Bauman, C. Verschraegen, S. Belinsky, et al., Cancer Chemother. Pharmacol., 69(2), 547 – 554 (2012).CrossRefPubMedGoogle Scholar
  6. 6.
    K. Raj and G. J. Mufti, Ther. Clin. Risk Manage., 2(4), 377 – 388 (2006).CrossRefGoogle Scholar
  7. 7.
    J. A. Beisler, J. Med. Chem., 21(2), 204 – 208 (1978).CrossRefPubMedGoogle Scholar
  8. 8.
    A. Strunecka, J. Patocka, and P. Connett, J. Appl. Biomed., 2(3), 141 – 150 (2004).Google Scholar
  9. 9.
    O. N. Zefirova and N. S. Zefirov, Vestn. Mosk. Univ., Ser. 2: Khim., 43(4), 251 – 256 (2002).Google Scholar
  10. 10.
    T. Ishikawa, Y. Fukase, T. Yamamoto, et al., Biol. Pharm. Bull., 21(7), 713 – 717 (1998).CrossRefPubMedGoogle Scholar
  11. 11.
    T. S. Bozhok and E. N. Kalinichenko, Izv. Nats. Akad. Nauk. Belarusi, Ser. Khim. Nauk, No. 3, 60 – 65 (2014).Google Scholar
  12. 12.
    A. Piskala and F. Sorm, Collect. Czech. Chem. Commun., 29(9), 2060 – 2076 (1964).CrossRefGoogle Scholar
  13. 13.
    E. N. Kalinichenko, T. S. Bozhok, T. N. Buravskaya, et al., Tr. Beloruss. Gos. Univ., 8(1), 235 – 240 (2013).Google Scholar
  14. 14.
    A. N. Mironov and N. D. Bunyatyan (eds.), Handbook for Preclinical Drug Trials [in Russian], Part 1, Grif i K, Moscow (2012), pp. 640 – 654.Google Scholar
  15. 15.
    T. Mosmann, J. Immunol. Methods, 65(1 – 2), 55 – 63 (1983).Google Scholar
  16. 16.
    J. E. van den Boogaart, E. N. Kalinichenko, T. L. Podkopaeva, et al., Eur. J. Biochem., 221(3), 759 – 768 (1994).CrossRefPubMedGoogle Scholar
  17. 17.
    D. K. Rogstad, J. L. Herring, J. A. Theruvathu, et al., Chem. Res. Toxicol., 22(6), 1194 – 1204 (2009).CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • T. S. Bozhok
    • 1
  • E. N. Kalinichenko
    • 1
  • B. B. Kuz’mitskii
    • 1
  • M. B. Golubeva
    • 1
  1. 1.Institute of Bioorganic ChemistryNational Academy of Sciences of BelarusMinskRepublic of Belarus

Personalised recommendations